Fresenius Kabi unveiled plans to expand its manufacturing operations in Wilson County, NC. The expansion project will bring hundreds of new jobs and more than $100 million in investment to Wilson, where the company currently employs more than 100 people.

“I’m proud that North Carolina is home to so many strong life sciences companies that make life-saving medicines,” said Governor Roy Cooper. “This expansion is welcome news for Eastern North Carolina and our entire state and shows once again that manufacturing thrives in North Carolina today.”

Fresenius Kabi’s plans in North Carolina include expansion of its current pharmaceutical production facility in Wilson and the construction of a new manufacturing facility, also in Wilson. Both sites will be dedicated to manufacturing products used in hospitals and clinics throughout the U.S. and Canada. Fresenius Kabi has owned its Wilson site, which specializes in the production of ready-to-administer syringes, since January 2016.

“Our strategy is to produce in the U.S. and to invest in products and operations that meet important customer needs while helping make health care more accessible for patients. We’re pleased to continue this approach at our site in North Carolina,” said Steven Nowicki, senior vice president, global operations, Fresenius Kabi North America.

Fresenius Kabi will add a variety of job functions with this expansion, including production specialists, engineers, scientists and managers.

“Manufacturing represents 22% of our state’s economic output and we’re one of the country’s largest centers for biotechnology,” said North Carolina Commerce Secretary Anthony Copeland. “We congratulate Fresenius Kabi for this decision, which helps North Carolina maintain its leadership in manufacturing and the life sciences.”

Fresenius Kabi recently broke ground on a $250 million expansion at its pharmaceutical manufacturing site in Melrose Park, IL. In total, the company employs more than 3,000 people in the U.S. and its U.S. headquarters is in Lake Zurich, IL.